Methylene Blue

Stomatitis

Mayo ClinicSmall moleculePhase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the Stomatitis cohort.

Asset / Sponsor	Phase	Rating
Datopotamab Deruxtecan AstraZeneca	Phase 4	BB
DEXAMETHASONE AstraZeneca	Phase 4	BB
Palifermin Swedish Orphan Biovitrum	Phase 3	B
MECLOCYCLINE SULFOSALICYLATE Mucosal Therapeutics	Phase 2	B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE US Oncology Research	Phase 2	B

View all 17 →

Same molecule, other indications

Methylene Blue is also rated in:

VasoplegiaDormant

BB

Indicative ·

69 / 100

Refractory ShockDormant

BB

Indicative ·

69 / 100

cirrhosis of liverDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.